Track market-moving stories before they get noisy

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW) announced April month-end assets under management of $1.83 trillion. Net outflows for April 2026 were $10.6 billion driven by a few large redemptions with net flow activity expected to moderate through the remainder of the quarter.

The below table shows the firm's assets under management as of April 30, 2026, and for the prior quarter- and year-end by asset class and in the firm's target date retirement portfolios.

As of

(in billions)

4/30/2026

3/31/2026

12/31/2025

 Equity

$              882

$            810

$            879

 Fixed income, including money market

218

215

212

 Multi-asset

665

625

627

 Alternatives

60

60

58

Total assets under management

$            1,825

$         1,710

$         1,776

Target date retirement portfolios

$               599

$            561

$            561

OTHER MATTERS

Certain statements in this release may represent "forward-looking information," including information relating to anticipated changes in the amount or composition of assets under management, flows into our investment funds, and other market conditions. For a discussion concerning risks and other factors that could affect future results, see the firm's 2025 Annual Report on Form 10-K.

T. Rowe Price (NASDAQ-GS: TROW) is a leading global asset management firm, entrusted with managing $1.83 trillion in client assets as of April 30, 2026, about two-thirds of which are retirement-related. Renowned for over 85 years of investment excellence, retirement leadership, and independent proprietary research, the firm leverages its long-standing expertise to ask better questions that can drive better investment decisions. Built on a culture of integrity and prioritizing client interests, T. Rowe Price empowers millions of investors worldwide to thrive amidst evolving markets. Visit troweprice.com/newsroom for news and public policy commentary.

SOURCE T. Rowe Price Group

Also from this source

Key Takeaways TROW's April AUM rose 6.7% sequentially to $1.83T despite $10.6B in net outflows.T. Rowe Price's equity AUM jumped 8.9% to $882B, while multi-asset products rose 6.4%.TROW's target date retirement portfolios increased 6.8% sequentially to $599B in April 2026. T. Rowe Price Group, Inc. (TROW - Free Report) announced its preliminary assets under management (AUM) of $1.83 trillion for April 2026. The figure reflected an increase of 6.7% from the prior month. The company experienced net outflows of $10.6 billion in April 2026, primarily driven by a few large redemptions.

Breakdown of TROW’s AUM PerformanceAt the end of April, T. Rowe Price’s equity products totaled $882 billion, an increase of 8.9% from the previous month. Fixed income (including money market) grew 1.4% to $218 billion. Furthermore, multi-asset products totaled $665 billion, an increase of 6.4% from the previous month.

Alternative products, valued at $60 billion, remained stable from the prior month.

T. Rowe Price registered $599 billion in target date retirement portfolios in April 2026, which rose 6.8% from the prior month.

Our Take on TROWT. Rowe Price continues to benefit from favorable market performance and strength across equity and multi-asset products, which supported AUM growth in April 2026. The company’s strong investment track record, diversified product portfolio and retirement-focused offerings are expected to support long-term asset growth. However, significant client redemptions and continued reliance on advisory fees remain concerns amid volatile market conditions.

T. Rowe Price’s Zacks Rank & Price PerformanceOver the past six months, TROW shares have risen 1.1% against the industry’s 4.4% decline.

Image Source: Zacks Investment Research

Currently, T. Rowe Price carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Performance of Other Asset ManagersFranklin Resources, Inc. (BEN - Free Report) reported a preliminary AUM of $1.74 trillion as of April 30, 2026, which increased 3.6% from the prior month.

The increase in preliminary AUM reflected the positive impact of markets and long-term net inflows of $4 billion, inclusive of $1 billion of long-term net outflows at Western Asset Management. Excluding Western Asset Management, BEN’s preliminary long-term net inflows were $5 billion.

Invesco (IVZ - Free Report) announced preliminary AUM of $2.34 trillion for April 2026, representing an 8.3% increase from the previous month.

In the reported month, IVZ’s net long-term inflows were $18.2 billion. Money market net inflows were $2.2 billion. AUM was positively impacted by favorable market returns, which increased the AUM by $151 billion. FX increased the AUM by $8.2 billion.

Newest episode of "The Angle" from T. Rowe Price features a conversation on leadership under pressure, institutional culture, and the outlook for business and markets

, /PRNewswire/ -- T. Rowe Price, a global investment management firm and a leader in retirement, announced the latest episode of "The Angle from T. Rowe Price," an investment-themed podcast focused on the forces shaping financial markets and the leaders navigating them.

David Solomon, Chairman & CEO of Goldman Sachs In the newest episode, host Eric Veiel, Head of Global Investments and Chief Investment Officer for T. Rowe Price, speaks with David Solomon, Chairman and CEO of Goldman Sachs, a global investment banking, securities, and investment management firm offering a wide array of services to clients ranging from corporations, governments, and individuals.

Veiel and Solomon discuss his path to leading Goldman Sachs, the importance of building a resilient culture inside a global institution, and how leaders make decisions in periods of uncertainty and rapid change. Their conversation also explores the evolving role of capital markets, how businesses adapt to shifting economic conditions, and what long-term leadership requires in an environment defined by complexity and constant reinvention.

"David brought a candid and experienced perspective to an important conversation that touched on leadership, adaptability, and the role major institutions play in navigating change," said Veiel. "What stood out was his focus on culture, decisiveness, and the need to keep evolving in response to shifting markets and client needs. It's a timely discussion for investors and business leaders thinking about what durable leadership looks like in a more dynamic environment."

ABOUT "THE ANGLE"

"The Angle" podcast brings listeners dynamic insights on the forces shaping financial markets, featuring the T. Rowe Price global investing team and special guests. Through engaging conversations, "The Angle from T. Rowe Price" aims to foster curiosity by asking better questions and delivering better insights, allowing investors to gain a deeper understanding of today's evolving market themes.

Launched in 2024, "The Angle" has explored a range of topics, including the artificial intelligence, health care innovation, forward-looking expectations for global markets,  key market drivers from the perspectives of some of the world's leading CEOs, and more recently taking a closer look at the future of the energy sector, speaking with experts across T. Rowe Price about the key themes shaping tomorrow's energy landscape.

This is the fourteenth episode of T. Rowe Price's C-suite podcast series. The first ten episodes, also available now, featured H. Lawrence Culp, Jr., chairman and CEO of GE Aerospace; Meredith Kopit Levien, president and CEO of The New York Times Company; Gary Guthart, CEO of Intuitive Surgical; Jensen Huang, founder and CEO of NVIDIA Corporation; Darren Woods, chairman and CEO of ExxonMobil; Harvey Schwartz, Chief Executive Officer and Director, and David Rubenstein, Co-Founder and Co-Chairman of the Board of Carlyle; Jane Fraser, CEO of Citi; Sarah Friar, CFO of OpenAI; Dave Ricks, CEO of Eli Lilly; Srini Gopalan, CEO of T-Mobile, Jim Farley, President and CEO of Ford Motor Company; and Kathy Warden, Chair, CEO, & President of Northrop Grumman. "The Angle from T. Rowe Price" is available across multiple platforms, including Spotify and Apple Podcasts. Future episodes will be announced as they are produced. For more information on the podcast please click here.

"The Angle from T. Rowe Price" is T. Rowe Price's second podcast series. "CONFIDENT CONVERSATIONS® on Retirement," which features T. Rowe Price experts sharing their perspectives on retirement-related topics, is in its fourth season.

ABOUT T. ROWE PRICE

T. Rowe Price (NASDAQ-GS: TROW) is a leading global asset management firm, entrusted with managing $1.83 trillion in client assets as of April 30, 2026, about two-thirds of which are retirement-related. Renowned for over 85 years of investment excellence, retirement leadership, and independent proprietary research, the firm leverages its longstanding expertise to ask better questions that can drive better investment decisions. Built on a culture of integrity and prioritizing client interests, T. Rowe Price empowers millions of investors worldwide to thrive amidst evolving markets. Visit troweprice.com/newsroom for news and public policy commentary.

SOURCE T. Rowe Price Group

A conversation on investing skill and the behaviors that shape investment outcomes

, /PRNewswire/ -- What can investors learn from stronger decision-making habits, including the role of discipline, self-awareness, and maintaining an explicit process?

In the latest episode of "The Angle from T. Rowe Price" titled "The Loser's Game: Lawrence Evans on Skill, Bias, and Better Decisions," Justin Thomson, head of the T. Rowe Price Investment Institute, speaks with Lawrence Evans, founder of Salomon Partners and an investment coach who works with professional investors and investment teams to develop better decision-making.

Lawrence Evans, Founder of Salomon Partners & Investment Coach "Lawrence offers a thoughtful perspective on what may separate stronger investors from the rest; not short-term results, but the discipline of process, the ability to recognize bias, and the commitment to continuous practice," says Thomson. "For investors, this episode highlights how better decision-making can be developed over time, and what it really means to be a skilled investor."

Key topics covered in this episode include:

How Evans defines investment skill and why near-term returns may be an incomplete measure of it. Why self-awareness, explicit discipline, and process may be more important than innate talent in investing. Which behavioral biases most often affect investment decisions, particularly when exiting positions. How AI may improve knowledge acquisition and pattern recognition, but human judgment and competence remain essential. Episodes of "The Angle" are available across multiple platforms, including Spotify and Apple Podcasts. Future episodes will be announced as they are produced. For more information on the podcast please click here.

ABOUT "THE ANGLE"
"The Angle" podcast brings listeners dynamic insights on the forces shaping financial markets, featuring the T. Rowe Price global investing team and special guests. Through engaging conversations, "The Angle" aims to foster curiosity by asking better questions and delivering better insights, allowing investors to gain a deeper understanding of today's evolving market themes.

Launched in 2024, "The Angle" has explored a range of investment-themed topics, including the blue economy, artificial intelligence, the 2024 U.S. presidential election, forward-looking expectations for global markets, key market drivers from the perspectives of some of the world's leading CEOs, the challenges and opportunities facing global energy markets, the power of financial history, and the future of AI.

"The Angle" is T. Rowe Price's second podcast series. "CONFIDENT CONVERSATIONS® on Retirement," which features T. Rowe Price experts sharing their perspectives on retirement-related topics, is in its fourth season.

ABOUT T. ROWE PRICE
T. Rowe Price (NASDAQ-GS: TROW) is a leading global asset management firm, entrusted with managing $1.83 trillion in client assets as of April 30, 2026, about two-thirds of which are retirement-related. Renowned for over 85 years of investment excellence, retirement leadership, and independent proprietary research, the firm leverages its longstanding expertise to ask better questions that can drive better investment decisions. Built on a culture of integrity and prioritizing client interests, T. Rowe Price empowers millions of investors worldwide to thrive amidst evolving markets. Visit troweprice.com/newsroom for news and public policy commentary.

SOURCE T. Rowe Price Group

Established in 1976, Government Money Fund and Tax-Free Income Fund continue to deliver on investors' needs to manage liquidity, taxes, and uncertainty amid heightened market volatility

, /PRNewswire/ -- T. Rowe Price, a premier global investment management firm and a leader in retirement, is marking 2026 with the 50th anniversaries for two mutual funds: T. Rowe Price Government Money Fund (Ticker: PRRXX) and T. Rowe Price Tax-Free Income Fund (Ticker: PRTAX). The anniversaries come at a time of heightened market volatility, underscoring investors' needs for liquidity management, tax-efficiency, and portfolio resilience. These were the first T. Rowe Price mutual funds in each category, and they join six other firm funds with track records of 50 years or more. *

From Cash on the Sidelines to Cash as a Strategy

In the mid-1970s, savers faced a dilemma. Inflation was surging and interest rates were rising, but bank regulations limited their ability to earn competitive yields on deposits. Leveraging what was then a recent innovation, the investment industry attracted savers with money market mutual funds, which invested in short-term securities such as Treasury bills, commercial paper, and repurchase agreements. 

This shift helped define cash as an asset class. As a response to growing client demand, T. Rowe Price launched the Government Money Fund in January 1976, then known as T. Rowe Price Prime Reserve Fund. The rise of money market mutual funds through the Seventies reshaped how investors used cash, as assets in the category grew from $2 billion to $74 billion during the last six years of the decade. By 1982, assets reached $200 billion; today, they stand at approximately $8 trillion1, according to the Investment Company Institute.

"Cash plays a critical role in investors' portfolios, especially during periods of uncertainty," said Alex Obaza, money market fund portfolio manager at T. Rowe Price. "We have seen many interest rate and market cycles over the last 50 years. All the while, money market funds have been anchors for investors, helping them manage volatility and maintain liquidity while earning competitive levels of income. Our commitment to rigorous research and disciplined liquidity management have served investors well."

As of March 31, 2026, T. Rowe Price manages approximately $69 billion in liquidity-focused strategies2, including approximately $34 billion in money market mutual funds.

Tax Reform Puts Tax-Exempt Bond Funds on Center Stage

Tax-free municipal bond funds were largely a creation of the Tax Reform Act of 1976, though the legacy of the federal tax exemption for interest on state and local bonds dates to the Revenue Act of 1913, which gave birth to the modern federal income tax. As Congress worked to expand the use of tax-exempt bonds as an economic development tool, T. Rowe Price launched the Tax-Free Income Fund in October 1976. Municipal bond funds gave investors a way to generate income that would not be subject to federal taxes while supporting essential infrastructure projects such as highways, bridges, water and sewage treatment plants, schools, electric and gas utilities, parks, mass transit, and more.

"Saving on taxes has long been a primary focus for many investors," said Jim Murphy, head of tax-exempt investing at T. Rowe Price. "Beyond that, tax-exempt bonds have been an effective diversifier as a complement in stock-heavy portfolios. As the municipal bond market has grown over the decades, it has become increasingly complex, making strong credit research and disciplined portfolio construction more important than ever in serving investors."

While markets, interest rate environments, and regulations have evolved significantly over the past 50 years, the role of cash and tax-free income remains constant. T. Rowe Price's money market and tax-free bond fund portfolio managers continue their research-driven approach to help investors effectively navigate change.

As of March 31, 2026, T. Rowe Price manages approximately $31 billion in tax-exempt portfolios, including approximately $21 billion in tax-exempt mutual funds.

*T. Rowe Price Mutual Funds With 50 or More Years of History

T. Rowe Price Balanced Fund (1939) T. Rowe Price Growth Stock Fund (1950) T. Rowe Price Small-Cap Stock Fund (1956) T. Rowe Price New Horizons Fund (1960) T. Rowe Price New Era Fund (1969) T. Rowe Price New Income Fund (1973) T. Rowe Price Government Money Fund (1976) T. Rowe Price Tax-Free Income Fund (1976) 1 $7.78 trillion for the week ended May 27, 2026.

2 Comprises money market mutual funds, money market trusts, money market separately managed accounts, and short-term investment funds, including stable value portfolios.

ABOUT T. ROWE PRICE

T. Rowe Price (NASDAQ-GS: TROW) is a leading global asset management firm, entrusted with managing $1.83 trillion in client assets as of April 30, 2026, about two-thirds of which are retirement-related. Renowned for over 85 years of investment excellence, retirement leadership, and independent proprietary research, the firm leverages its longstanding expertise to ask better questions that can drive better investment decisions. Built on a culture of integrity and prioritizing client interests, T. Rowe Price empowers millions of investors worldwide to thrive amidst evolving markets. Visit troweprice.com/newsroom for news and public policy commentary.

IMPORTANT INFORMATION

T. Rowe Price Government Money Fund: You could lose money by investing in the fund. Although the fund seeks to preserve the value of your investment at $1.00 per share, it cannot guarantee it will do so. An investment in the fund is not a bank account and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency. T. Rowe Price Associates, Inc., is not required to reimburse the fund for losses, and you should not expect that T. Rowe Price Associates, Inc., will provide financial support to the fund at any time, including during periods of market stress.

T. Rowe Price Tax-Free Income Fund: Interest rates: A rise in interest rates typically causes the price of a fixed rate debt instrument to fall and its yield to rise. Conversely, a decline in interest rates typically causes the price of a fixed rate debt instrument to rise and the yield to fall. Municipal securities: The fund may be highly impacted by events tied to the overall municipal securities markets, which can be very volatile and significantly affected by unfavorable legislative or political developments and adverse changes in the financial conditions of municipal securities issuers and the global, national, and/or local economies. Taxes: Some income may be subject to the federal alternative minimum tax. Capital gains, if any, are generally taxable.

Consider the investment objectives, risks, and charges and expenses carefully before investing. For a prospectus or, if available, a summary prospectus containing this and other information, visit troweprice.com/prospectus. Read it carefully.

All investments are subject to market risk, including the possible loss of principal. See each fund's prospectus for more detail on the fund's Principal Risks.

T. Rowe Price Investment Services, Inc., distributor, T. Rowe Price funds

All T. Rowe Price data as of March 31, 2026, and data from the Investment Company Institute as of May 27, 2026.

SOURCE T. Rowe Price Group

Key Takeaways TROW and LAZ are diversified asset managers with global reach and multiple revenue streams.TROW is expanding via partnerships and alternatives while strengthening its retirement platform.LAZ is growing through acquisitions and building its private capital and advisory businesses. T. Rowe Price Group, Inc. (TROW - Free Report) and Lazard, Inc. (LAZ - Free Report) are well-established investment management firms with broad capabilities across equities, fixed income, multi-asset and alternative investments. While T. Rowe Price primarily focuses on investment management services for individual and institutional clients, Lazard complements its asset-management operations with a leading financial-advisory business. Both firms benefit from diversified client bases and global operating platforms, though differences in their business mix, growth strategies and revenue drivers could influence their future performance.

The asset management industry has been facing pressure from rising technology and artificial intelligence (AI)-related expenses, which may weigh on near-term profitability despite long-term efficiency gains. The ongoing shift toward low-cost passive products continues to compress fees and intensify competition, prompting firms to pursue mergers and partnerships to gain scale. In addition, recent private credit concerns could moderate near-term flows into higher-fee alternative strategies. Nevertheless, steady inflows are supporting growth in assets under management (AUM).

Against this backdrop, investors naturally ask: Which firm, TROW or LAZ, has better potential? To answer that, we need to examine their fundamentals more closely.

The Case for TROWT. Rowe Price has been strengthening its platform through strategic partnerships and acquisitions. In September 2025, the company partnered with Goldman Sachs (GS - Free Report) to develop public and private market solutions tailored for retirement and wealth investors, with additional retirement-focused offerings expected to launch later in 2026. Earlier in 2025, it partnered with Aspida to manage public and private assets, expanding the company’s presence in insurance asset management. Together, these initiatives have strengthened the company's investment platform and diversified its revenue streams, supporting long-term growth prospects.

Meanwhile, T. Rowe Price’s diversified AUM across various asset classes, client bases and geographies provides stability and supports sustainable earnings. The company's efforts to expand its retirement, insurance and alternative investment capabilities have contributed to favorable asset flows and asset growth over the years. Market appreciation and continued strength in multi-asset and fixed-income products have further supported this trend. A strong brand, consistent investment track record and solid business volumes are expected to keep supporting AUM growth in the upcoming period.

At T. Rowe Price, organic growth remains a key contributor to revenue momentum. The company's efforts to enhance investment capabilities, broaden distribution reach and introduce new products are expected to support client engagement and asset gathering. As TROW continues to expand its alternative investment and retirement offerings, its revenue base is likely to remain supported by a diversified mix of fee-generating assets.

Further, T. Rowe Price exhibits a strong liquidity position. As of March 31, 2026, the company held $6.89 billion in liquid assets, including cash and cash equivalents as well as investments, compared with total liabilities of $2.52 billion. The company's solid liquidity profile is expected to support strategic investments and business growth initiatives going forward.

The Case for LAZLazard has also been expanding its platform through acquisitions and partnerships. In May 2026, the company announced the acquisition of Campbell Lutyens, strengthening its private capital advisory capabilities and expanding its reach across institutional investors and financial sponsors. Earlier in 2025, Lazard formed an alliance with Arini Capital Management, enhancing its private credit capabilities.

Building on these initiatives, Lazard has witnessed steady growth in its AUM balance over the years. The company's efforts to expand its asset-management platform through acquisitions and private-market initiatives have supported asset growth, while strong client engagement and demand across investment strategies have remained encouraging. Driven by these factors and favorable industry dynamics, the company's AUM balance is expected to continue growing in the coming quarters.

Organic growth also remains a key strength at Lazard, as reflected in its revenue growth trend. The company's diversified asset-management and advisory businesses provide multiple avenues for revenue generation. Continued strength in asset management, supported by a growing AUM base, and a recovery in deal-making activity are expected to drive top-line growth. Further, management's ongoing efforts to expand its private capital and advisory businesses are expected to support revenue momentum and long-term earnings growth.

However, despite benefiting from investment-grade credit ratings and a well-laddered debt maturity profile that provides access to funding at favorable rates, Lazard's liquidity position appears relatively constrained. As of March 31, 2026, the company held cash and cash equivalents of $1.02 billion against senior debt of $1.69 billion.

How Do Estimates Compare for TROW & LAZ?The Zacks Consensus Estimate for TROW’s 2026 and 2027 revenue suggests year-over-year increases of 3.2% and 2.2%, respectively. Meanwhile, the consensus estimate for earnings suggests declines of 0.9% in 2026 and 0.3% in 2027. Over the past month, earnings estimates for both 2026 and 2027 have been revised upward.

Estimates Revision Trend
Image Source: Zacks Investment Research

The consensus mark for LAZ’s 2026 and 2027 sales suggests year-over-year increases of 11.7% and 22.2%, respectively. Also, the consensus estimate for earnings indicates a 16.8% and 67.8% rise for 2026 and 2027, respectively. Earnings estimates for both years have remained unchanged over the past 30 days.

Estimates Revision Trend
Image Source: Zacks Investment Research

TROW & LAZ: Price Performance & ValuationOver the past three months, TROW and LAZ shares gained 17.1% and 7.4%, respectively, compared with the S&P 500 Index’s growth of 9.1%.

Price Performance
Image Source: Zacks Investment Research

From a valuation standpoint, TROW is currently trading at a forward 12-month price-to-earnings (P/E) multiple of 11.02X, while LAZ is currently trading at a forward 12-month P/E multiple of 12.57X. Here, TROW stock is cheaper than LAZ.

Price-to-Earnings F12M
Image Source: Zacks Investment Research

TROW or LAZ: Which Stock Has Better Potential?Both T. Rowe Price and Lazard are established asset managers with diversified business models, growing alternative-investment capabilities and expanding private-market franchises. Each company benefits from solid asset-management operations, broad client relationships and strategic initiatives aimed at supporting long-term growth across traditional and alternative asset classes.

However, TROW benefits from a stronger liquidity profile and a more diversified and steadily growing AUM base. The company's expansion across retirement, insurance and alternative-investment solutions, coupled with its strong investment performance and disciplined capital-return strategy, positions it well for sustainable growth.

Although Lazard's earnings and revenue growth estimates appear stronger on paper, much of that growth depends on the successful execution of acquisitions and a sustained recovery in advisory activity, which can be more cyclical and market-dependent.

Additionally, T. Rowe Price trades at a discount to Lazard, offering investors a more attractive valuation while maintaining a stronger balance sheet and established organic-growth drivers. Given its financial strength, diversified business model, expanding retirement and alternatives platform, and compelling valuation, T. Rowe Price appears better positioned to deliver sustainable long-term shareholder value.

At present, T. Rowe Price carries a Zacks Rank #3 (Hold), while Lazard has a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Oil prices may normalize some but are likely to remain structurally higher

, /PRNewswire/ -- T. Rowe Price, a global investment management firm and a leader in retirement, released its midyear outlook for global financial markets for the remainder of 2026. Fiscal expansion and AI investment have underpinned stronger-than-expected U.S. growth, but leadership in stocks has begun to broaden beyond mega-cap technology companies. In fixed income, while government bond yields have stayed under pressure from deficits and issuance, credit markets have been resilient. The risk for investors is mistaking resilience for calm, as the market regime is changing.

Key points from the 2026 Midyear Market Outlook include:

Markets have remained relatively sturdy, but rising geopolitical tensions are prompting a reassessment of long-standing security assumptions, with greater emphasis on cyber capabilities and localized defense capacity. This is creating central bank policy dispersion, creating opportunities in rates and currency markets.Manufacturing is recovering after a multi-year downturn, adding a new source of inflation pressure just as markets had hoped central banks could continue cutting interest rates. This is likely to make inflation broader and more durable than markets expect.Supply shocks have sparked a global push for energy security. The Middle East conflict has exposed how fragile global energy supply chains have become. This has sharpened investor focus on industries positioned to benefit from a world of scarcer supply.AI-related upside is broadening beyond the most obvious beneficiaries to industrial and hardware technology companies enabling the infrastructure build-out. The focus is shifting from the size of hyperscaler spending to where that spending flows, such as power, data centers, electrical equipment, cooling, connectivity, construction, and services.The long-running dynamic of stock market returns being dominated by a small group of mega-cap, asset-light platforms is shifting. These companies are being pulled into a capital-intensive investment race, which can pressure free cash flow and alter return profiles. For investors and active managers, the implications are significant.QUOTES

Chris Kushlis, chief emerging market macro strategist

"Geopolitical tensions are accelerating the fragmentation of the global economy as governments prioritize energy security, domestic industrial capacity, and diversified supply chains. This is likely to prove structurally inflationary, increasing costs through reshoring, tariffs, supply-chain duplication, higher defense spending, and more volatile central bank policy paths."

Razan Nasser, credit analyst

"Credit markets have absorbed the year's geopolitical shocks better than might have been expected. But repeated shocks could test resilience if higher energy prices and more volatile inflation expectations begin to weigh on financial conditions and risk appetite. Central banks are coming under pressure to compromise their inflation targets."

Adam Marden, portfolio manager, Fixed Income

"Markets have not priced in the possibility of more persistent inflation tied to the upturn in global manufacturing and more expensive raw materials. Markets are trying to look through short-term pressures, but investors may be disappointed by the structural inflation that remains after the immediate energy supply crunch."

Rick de los Reyes, head of commodities and sector portfolio manager

"Declining oil productivity and elevated geopolitical risk are likely to keep prices structurally higher than before the current Middle East conflict. We see opportunities in businesses tied to energy scarcity, such as oil field services firms and producers in developed countries of critical minerals such as tungsten and uranium."

Jason Adams, sector portfolio manager, Equity

"AI is no longer just a technology story. It is increasingly becoming a broader industrial and infrastructure investment cycle. The most attractive opportunities sit with companies that can monetize complexity, power intensity, connectivity, and execution, rather than simply benefiting from backlog growth or AI enthusiasm."

David Eiswert, portfolio manager, Equity

"Market leadership is broadening across sectors and geographies, widening the gap between companies that can translate higher investment into stronger returns on capital and those that cannot. This creates a richer opportunity set for active investors who can distinguish between capital spending that enhances returns and spending that dilutes them. This is more than market rotation. It's a shift from concentration to dispersion, and from passive exposure to active selection."

ABOUT T. ROWE PRICE
Founded in 1937, T. Rowe Price (NASDAQ: TROW) helps people around the world achieve their long-term investment goals. As a large global asset management company known for investment excellence, retirement leadership, and independent proprietary research, the firm is built on a culture of integrity that puts client interests first. Investors rely on the award-winning firm for its retirement expertise and active management approach of equity, fixed income, alternatives, and multi-asset investment capabilities. T. Rowe Price manages USD $1.89 trillion in assets under management as of May 31, 2026, and serves millions of clients globally. News and other updates can be found on Facebook, Instagram, LinkedIn, X, YouTube, and troweprice.com/newsroom.

IMPORTANT INFORMATION
This material is being furnished for general informational and/or marketing purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice. Prospective investors are recommended to seek independent legal, financial, and tax advice before making any investment decision. The T. Rowe Price group of companies, including T. Rowe Price Associates, Inc., and/or its affiliates, receives revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested. Active investing may have higher costs than passive investing and may underperform the broad market or passive peers with similar objectives.

T. Rowe Price Investment Services, Inc., distributor. T. Rowe Price Associates, Inc., investment adviser.

T. Rowe Price Associates, Inc., and T. Rowe Price Investment Services, Inc., are affiliated companies.
© 2026 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/or apart, trademarks of T. Rowe Price Group, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/t-rowe-price-2026-midyear-market-outlook-fragmentation-ai-and-inflation-reshape-financial-markets-amid-heightened-geopolitical-tensions-302796872.html

SOURCE T. Rowe Price Group

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.93% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Roper Technologies (ROP - Free Report) Based in Sarasota, FL, Roper Technologies, Inc. designs, manufactures and distributes software and technology enabled products and solutions. It caters to selected segments of a broad range of markets, which include legal, healthcare, government, food, transportation, oil & gas, medical, and other niche industries.

ROP is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.22; value investors should take notice.

Eight analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.44 to $21.88 per share. ROP boasts an average earnings surprise of +1.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, ROP should be on investors' short list.

On May 11, 2026, Roper Technologies Inc ROP shares fell 4.2% to a current price of $328.80. The stock is currently trading within a 52-week range of $313.07 to $584.03, indicating significant volatility over the past year.

GF Value™ verdict: Current price is $328.80 vs GF Value™ of $678.77, representing a potential upside of 51.6%. GF Score™ of 79/100 indicates the stock is above average based on key performance metrics. Notable signal: There have been no insider transactions in the last 3 months. Is ROP Overvalued or Undervalued? Based on the current price of $328.80 and the GF Value™ estimate of $678.77, Roper Technologies Inc appears significantly undervalued with a margin of safety of 51.6%. This suggests that the stock may present a compelling opportunity for investors looking for undervalued assets. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

While the stock's undervaluation might indicate a buying opportunity, it is essential to consider potential risks, including market volatility and the company's financial strength, which is rated 5/10. The GF Valuation label classifies ROP as significantly undervalued, reinforcing the idea that there may be room for price appreciation if market conditions improve.

How Does ROP's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 20.5x 36.4x (5-Year Median) Forward P/E 15.3x N/A ROP's current P/E (TTM) of 20.5x is significantly below its 5-year median P/E of 36.4x, reflecting that the stock is trading well below its historical valuation. This analysis aligns with the GF Value™ verdict of undervaluation, indicating that ROP might be a more attractive investment than it has been in the past based on earnings potential.

What Does ROP's GF Score™ Tell Us? Metric Rating GF Score™ 79 Financial Strength 5/10 Profitability 9/10 Growth 10/10 Valuation 2/10 Momentum 2/10 ROP's GF Score™ of 79/100 indicates a strong performance in key areas such as profitability and growth, with scores of 9/10 and 10/10 respectively. However, the stock's valuation is rated low at 2/10, suggesting that while the company's fundamentals are strong, the current market price does not reflect its growth potential. The financial strength score of 5/10 indicates moderate stability, which could be a concern in a volatile market.

What Are Insiders Doing with ROP Stock? There have been no insider transactions involving Roper Technologies Inc in the last three months. This lack of activity may suggest that insiders are either confident in the current valuation or are waiting for more favorable conditions to engage in buying or selling. Investors often watch insider activity as a signal, but in this case, the absence of transactions leaves uncertainty regarding insider sentiment.

What This Means for Investors Based on the GF Value™ analysis, Roper Technologies Inc is currently undervalued, presenting a potential opportunity for long-term investors. However, the low valuation rank and financial strength score warrant caution, as they indicate that there may be underlying concerns that could affect future performance.

For the complete analysis, visit the Roper Technologies Inc ROP stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is ROP's GF Score™?

ROP's GF Score™ is 79/100, indicating that it is above average compared to other stocks based on key performance metrics.

Is ROP overvalued or undervalued?

ROP is currently undervalued with a GF Value™ of $678.77 compared to its current price of $328.80, suggesting significant upside potential.

What is ROP's P/E ratio?

ROP's P/E ratio is 20.5x (TTM), which is 44% below its 5-year median P/E of 36.4x, indicating that the stock is trading well below its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

There's a likely a subset of S&P 500names that are too cheap—and ready to rally.

Key Takeaways ROP's Application Software revenues rose 11.5% year over year to $1.19 billion in Q1 2026.Roper sees more than mid-single-digit organic revenue growth in the segment for the rest of 2026.ROP benefits from SaaS adoption, GenAI innovation and strong recurring revenue momentum. Roper Technologies, Inc. (ROP - Free Report) continues to benefit from strength in its Application Software segment. Strong momentum across its Aderant, Deltek, Vertafore, PowerPlan and CentralReach businesses is aiding the segment. Also, it is witnessing strength in the project-based private sector, higher education, property and casualty insurance, and legal markets.

The growing adoption of SaaS solutions and continued GenAI innovation are key catalysts to Aderant’s growth. Solid demand for SaaS solutions in the private sector is supporting the Deltek business. The Vertafore business is witnessing strong momentum driven by excellent enterprise delivery capabilities to the largest customers in the market, which has also resulted in strong annual recurring revenue (ARR) growth.

Strong customer retention and adoption of new SaaS solutions bode well for the PowerPlan business. Robust momentum in the CentralReach business, driven by higher recurring revenues, is a boon for the segment. In the first quarter of 2026, the Application Software segment’s revenues totaled $1.19 billion, representing 56.9% of the quarter’s top line.  The segment’s revenues increased 11.5% on a year-over-year basis.

Backed by strong business performance, Roper expects organic revenues from this segment to increase by more than mid-single digits for the rest of 2026. The segment is likely to remain the company’s key growth driver in the near term, backed by a stable stream of recurring revenues.

Segment Snapshot of ROP’s PeersAmong its major peers, Atlassian Corp.’s (TEAM - Free Report) AI-powered capabilities are seeing rapid adoption. Atlassian’s AI-powered Rovo platform and automation tools are boosting growth in its premium and enterprise offerings, driven by strong demand for AI-based workflows. Atlassian’s focus on adding generative AI features to its collaboration software is expected to support long-term revenue growth.

Roper's other peer, Autodesk, Inc.’s (ADSK - Free Report) performance is gaining from new business growth, steady subscription renewal rates and strong competitive performance. Higher demand for its cloud-based products, mobile solutions and design suites also bodes well for Autodesk. Autodesk’s aggressive push into cloud infrastructure and AI integration demands substantial capital deployment for data centers, computing resources and specialized talent acquisition.

ROP’s Price Performance, Valuation & EstimatesShares of Roper have lost 1.1% in the past three months compared with the industry’s decline of 8.7%.

Image Source: Zacks Investment Research

From a valuation standpoint, ROP is trading at a forward price-to-earnings ratio of 14.06X compared with the industry’s average of 17.18X. Roper carries a Value Score of B.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for ROP’s 2026 earnings has increased over the past 60 days.

Image Source: Zacks Investment Research

Roper currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

May 19, 2026 14:00 ET  | Source: Roper Technologies, Inc.

SARASOTA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that its Board of Directors has approved a dividend of $0.91 per share payable on July 22, 2026, to stockholders of record on July 8, 2026.

About Roper Technologies

Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 1000. Roper has a proven, long-term track record of compounding cash flow and shareholder value. The Company operates market leading businesses that design and develop vertical software and technology enabled products for a variety of defensible niche markets. Roper utilizes a disciplined, analytical, and process-driven approach to redeploy its excess capital toward high-quality acquisitions. Additional information about Roper is available on the Company’s website at www.ropertech.com.

Contact information:
Investor Relations
941-556-2601
[email protected]

Illumia, a leading provider of technology solutions that power payments, access, foodservice and operational experiences across higher education, healthcare, senior living and corporate environments, today announced that Laura Newell-McLaughlin has been named Chief Operating Officer.

In this role, Newell-McLaughlin will lead the next phase of Illumia’s operational unification, with responsibility for Enterprise Applications, Banking Operations, Program Management, AI Transformation, Client Support, Supply Chain, and Chennai Operations. She will focus on strengthening the systems, processes and operating capabilities that support Illumia’s product, technology and commercial teams as the company continues to scale under its unified brand.

Newell-McLaughlin will also play a central role in embedding generative AI across Illumia’s operations, helping the company increase efficiency, improve execution speed, and remove friction from internal workflows and customer-facing support processes.

“Laura has a deep understanding of our business, our customers, and the operational discipline required to serve mission-critical organizations where reliability matters every day,” said Greg Brown, CEO of Illumia. “Her leadership will be critical as we continue to build the operating backbone that enables our teams to move faster, scale with discipline, and bring practical AI into the workflows that help our people and customers succeed.”

Newell-McLaughlin brings more than 30 years of experience in payments, campus commerce, product strategy, and operational leadership. She has been part of the company’s evolution since 1993 through Academic Management Services, Sallie Mae, Higher One, Blackboard, and Transact Campus. Most recently, she served as Chief Commercial Officer, where she helped shape the company’s payments strategy, strategic partnerships, and product direction for higher education institutions.

Earlier in her career, Newell-McLaughlin held a leadership role at Sallie Mae. She is widely recognized for her expertise in payment strategy, performance, and the operational needs of complex campus environments.

Newell-McLaughlin holds a Bachelor of Arts in Communications, with a concentration in Business Management from Rhode Island College.

About Illumia

Illumia (formerly Transact + CBORD), a business unit of Roper Technologies (Nasdaq: ROP), powers the payments, access, foodservice, and credentialing systems that more than 10,000 higher education, healthcare, and senior living institutions depend on every day. Its unified platform delivers the stability, security, and reliability these environments demand — where downtime is not an option. Illumia transforms the experiences organizations deliver to their communities while modernizing how those organizations operate. For more information, visit illumiatech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260518965073/en/

The Application Software segment remains the cornerstone of Roper Technologies, Inc.’s (ROP - Free Report) growth strategy, delivering consistent expansion supported by healthy demand across its Aderant, Deltek, Vertafore, PowerPlan and CentralReach businesses. Demand remains strong across key end markets, including private-sector project management, higher education, property and casualty insurance, and legal services.

The segment is also benefiting from increasing adoption of SaaS offerings and ongoing GenAI innovation. Aderant is gaining from strong demand for its SaaS solutions, while Deltek continues to see solid traction in the private sector. Vertafore’s growth is being fueled by strong execution with large enterprise customers, leading to robust annual recurring revenue (ARR) expansion. Meanwhile, PowerPlan is supported by high customer retention and growing uptake of new SaaS products, and CentralReach continues to generate strong recurring revenue growth.

In the first quarter of 2026, the Application Software segment accounted for nearly 57% of Roper’s total revenues. Segment revenues increased 11.5% year over year to $1.19 billion. This performance highlights the segment’s growing scale and strategic importance within the company’s portfolio.

Looking ahead, Roper expects the segment to maintain solid momentum by delivering organic revenue growth of more than mid-single digits through the remainder of 2026, supported by its subscription-based revenue streams, expanding software adoption and continued product enhancements. These factors position the Application Software segment to remain a major contributor to Roper’s long-term growth and profitability.

Segment Snapshot of ROP’s PeersAmong its major peers, Atlassian Corp.’s (TEAM - Free Report) AI-powered capabilities are seeing rapid adoption. Atlassian’s AI-powered Rovo platform and automation tools are boosting growth in its premium and enterprise offerings, driven by strong demand for AI-based workflows. Atlassian’s focus on adding generative AI features to its collaboration software is expected to support long-term revenue growth.

Roper's other peer, Autodesk, Inc.’s (ADSK - Free Report) performance is gaining from new business growth, steady subscription renewal rates and strong competitive performance. Higher demand for its cloud-based products, mobile solutions and design suites also bodes well for Autodesk. Autodesk’s aggressive push into cloud infrastructure and AI integration demands substantial capital deployment for data centers, computing resources and specialized talent acquisition.

ROP’s Price Performance, Valuation & EstimatesShares of Roper have lost 9.4% in the past three months compared with the industry’s decline of 4.4%.

Image Source: Zacks Investment Research

From a valuation standpoint, ROP is trading at a forward price-to-earnings ratio of 14.56X compared with the industry’s average of 18.91X. Roper carries a Value Score of B.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for ROP’s 2026 earnings has increased 2.2% over the past 60 days.

Image Source: Zacks Investment Research

Roper currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways Roper's Technology Enabled Products segment delivered 7.1% organic revenue growth in Q1 2026.ROP is seeing strong demand for NDI tracking solutions and Verathon's BFlex and GlideScope offerings.Roper expects total 2026 revenue growth of about 8% and organic growth of roughly 5-6%. Roper Technologies, Inc. (ROP - Free Report) is witnessing persistent strength in the Technology Enabled Products segment, driven by strong momentum in medical products businesses. Growth in demand for electromagnetic tracking solutions across neurological, cardiac and orthopedic precision measurement applications is fostering the growth of the NDI business within the segment.

Solid performance of the Verathon business, supported by strength across single-use BFlex & GlideScope offerings, bodes well for the segment. The company remains optimistic about new product introductions planned for the rest of the year. Also, the growing popularity of its cloud-based software solution is likely to aid the Neptune business. In first-quarter 2026, the segment’s organic revenues increased 7.1% on a year-over-year basis. For the balance of the year, Roper expects the segment’s organic revenues to increase in the mid-single-digit range.

Also, the growing popularity of its products and solutions across the Deltek, Vertafore, PowerPlan and Aderant businesses is driving ROP’s Application Software segment. Apart from this, strong momentum across the ConstructConnect, Subsplash and SoftWriters businesses, augurs well for its Network Software unit. Driven by strength across its businesses, the company expects total revenues to increase approximately 8% in 2026 from the year-ago level. Organic revenues are estimated to rise approximately 5-6% year over year.

Performance Snapshot of ROP’s PeersAmong its major peers, Agilent Technologies, Inc. (A - Free Report) has a significant exposure to the healthcare industry, which holds long-term prospects. Agilent’s strength in liquid chromatography systems and components and liquid chromatography mass spectrometry systems remains a plus. The broad-based demand in pharma, diagnostics and applied markets remains a tailwind for Agilent.

Rockwell Automation, Inc. (ROK - Free Report) is benefiting from broadening its portfolio of hardware and software products, solutions and services. In Rockwell's Life Science business, the combination of FactoryTalk Pharma Suite MES and FactoryTalk Optix helped secure a competitive win for an active pharma ingredient application. For fiscal 2026, Rockwell raised both its reported and organic sales growth view to 5-9% year over year.

ROP’s Price Performance, Valuation and EstimatesShares of Roper have gained 5.2% in the past month compared with the industry’s growth of 2.1%.

Image Source: Zacks Investment Research

From a valuation standpoint, ROP is trading at a forward price-to-earnings ratio of 14.58X compared with the industry’s average of 17.57X. Roper carries a Value Score of C.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for ROP’s 2025 and 2026 earnings has increased over the past 60 days.

Image Source: Zacks Investment Research

Roper currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical Services (WST - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.

Therefore, the Zacks rating upgrade for West Pharmaceutical basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for West Pharmaceutical imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for West PharmaceuticalThis medical device company is expected to earn $8.50 per share for the fiscal year ending December 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for West Pharmaceutical. Over the past three months, the Zacks Consensus Estimate for the company has increased 12.2%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of West Pharmaceutical to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Posted by Defense World Staff on Apr 29th, 2026

Comerica Bank boosted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 31.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 56,693 shares of the medical instruments supplier’s stock after acquiring an additional 13,680 shares during the period. Comerica Bank owned 0.08% of West Pharmaceutical Services worth $15,599,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Anchyra Partners LLC acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter worth about $611,000. Concurrent Investment Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 39.3% during the 4th quarter. Concurrent Investment Advisors LLC now owns 1,102 shares of the medical instruments supplier’s stock worth $303,000 after purchasing an additional 311 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of West Pharmaceutical Services by 300.3% during the 4th quarter. Teacher Retirement System of Texas now owns 38,157 shares of the medical instruments supplier’s stock worth $10,499,000 after purchasing an additional 28,626 shares during the last quarter. M&T Bank Corp boosted its stake in shares of West Pharmaceutical Services by 523.7% during the 4th quarter. M&T Bank Corp now owns 128,638 shares of the medical instruments supplier’s stock worth $35,393,000 after purchasing an additional 108,013 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of West Pharmaceutical Services by 13.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,919 shares of the medical instruments supplier’s stock worth $6,581,000 after purchasing an additional 2,922 shares during the period. 93.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes A number of research analysts have weighed in on the company. Weiss Ratings raised West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 price target on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Jefferies Financial Group reissued a “buy” rating and set a $295.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Morgan Stanley set a $315.00 price target on West Pharmaceutical Services in a research note on Monday. Finally, Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus price target of $322.89.

View Our Latest Stock Analysis on WST

West Pharmaceutical Services Price Performance WST opened at $292.67 on Wednesday. The company’s 50 day simple moving average is $255.14 and its 200 day simple moving average is $262.77. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. West Pharmaceutical Services, Inc. has a 1 year low of $202.79 and a 1 year high of $322.34. The stock has a market capitalization of $20.68 billion, a PE ratio of 39.13, a P/E/G ratio of 2.65 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.68 million. During the same period last year, the company earned $1.45 earnings per share. The company’s quarterly revenue was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, sell-side analysts expect that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current year.

West Pharmaceutical Services Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services’s payout ratio is 11.76%.

West Pharmaceutical Services declared that its Board of Directors has authorized a share repurchase plan on Tuesday, February 17th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 5.6% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

West Pharmaceutical Services Company Profile (Free Report)

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

Read More Five stocks we like better than West Pharmaceutical Services

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEComerica Bank Sells 2,858 Shares of Synopsys, Inc. $SNPS

NEXT HEADLINE »Comerica Bank Has $15.42 Million Position in Watsco, Inc. $WSO

From a technical perspective, West Pharmaceutical Services, Inc. (WST - Free Report) is looking like an interesting pick, as it just reached a key level of support. WST's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typically, a golden cross involves the 50-day and the 200-day moving averages, since bigger time periods tend to form stronger breakouts.

Golden crosses have three key stages that investors look out for. It starts with a downtrend in a stock's price that eventually bottoms out, followed by the stock's shorter moving average crossing over its longer moving average and triggering a trend reversal. The final stage is when a stock continues the upward climb to higher prices.

A golden cross is the opposite of a death cross, another technical event that indicates bearish price movement may be on the horizon.

WST could be on the verge of a breakout after moving 17.5% higher over the last four weeks. Plus, the company is currently a #1 (Strong Buy) on the Zacks Rank.

Looking at WST's earnings expectations, investors will be even more convinced of the bullish uptrend. For the current quarter, there have been 6 changes higher compared to none lower over the past 60 days, and the Zacks Consensus Estimate has moved up as well.

Given this move in earnings estimates and the positive technical factor, investors may want to keep their eye on WST for more gains in the near future.

Investors interested in Medical - Dental Supplies stocks are likely familiar with Align Technology (ALGN - Free Report) and West Pharmaceutical Services (WST - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Align Technology and West Pharmaceutical Services are both sporting a Zacks Rank of #2 (Buy) right now. This means that both companies have witnessed positive earnings estimate revisions, so investors should feel comfortable knowing that both of these stocks have an improving earnings outlook. But this is just one factor that value investors are interested in.

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.

The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.

ALGN currently has a forward P/E ratio of 14.87, while WST has a forward P/E of 38.33. We also note that ALGN has a PEG ratio of 1.44. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. WST currently has a PEG ratio of 2.76.

Another notable valuation metric for ALGN is its P/B ratio of 2.91. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, WST has a P/B of 7.7.

These are just a few of the metrics contributing to ALGN's Value grade of B and WST's Value grade of D.

Both ALGN and WST are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that ALGN is the superior value option right now.

West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2026 Transcript

CompaniesMay 20 (Reuters) - West Pharmaceutical Services (WST.N), opens new tab said on Wednesday it has ​restored operations across its sites after a cybersecurity attack earlier this ‌month and expects the incident to have no material impact on its 2026 financial outlook.

The company said it is continuing its investigation, but has ​not seen any further unauthorized access.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Shares of the company ​were up about 2% in after hours trading.

The medical ⁠equipment maker detected an intrusion on May 4 and confirmed ​a material cybersecurity attack on May 7 involving data being taken ​and systems being locked.

Analysts at Evercore ISI said, "We are incrementally encouraged by WST's ability to quickly return to normal operations and offset any cyberattack-related disruption."

"WST ​will likely leverage flex capacity and 24/7 operations, which management ​had previously highlighted as a lever to offset disruption," the analysts added.

The company ‌said after ⁠the incident it took systems offline globally, informed law enforcement and brought in external cyber experts to respond to the incident.

It has since restored core systems and restarted key processes such as ​manufacturing, receiving and ​shipping at all ⁠locations.

The company is now fully operational across manufacturing, supply chain and commercial sites globally, it said.

The ​company said the review is ongoing, including assessing ​how much ⁠data may have been affected.

The company said the incident has not had and is not expected to have a material impact on ⁠its ​2026 second-quarter or full-year forecast.

Stryker (SYK.N), opens new tab and ​Intuitive Surgical (ISRG.O), opens new tab also reported cybersecurity incidents in March, while Medtronic (MDT.N), opens new tab disclosed a similar incident ​in April.

Reporting by Sahil Pandey in Bengaluru; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles., opens new tab

On May 21, 2026, West Pharmaceutical Services Inc WST shares rose 3.5% to $316.13. This uptick comes amidst a positive price performance, with shares having traded between a 52-week high of $330.88 and a low of $203.74.

GF Value™ verdict: The current price is $316.13, which is 12.1% below the GF Value™ estimate of $359.79.GF Score™: With a score of 96/100, WST is rated as a strong investment opportunity.Most notable signal: With a Financial Strength rating of 9/10, WST demonstrates robust financial health. Is WST Overvalued or Undervalued? According to the GF Value™, West Pharmaceutical Services Inc WST is currently undervalued, trading at $316.13 compared to an estimated fair value of $359.79. This indicates a margin of safety of approximately 12.1%, suggesting that the shares are priced lower than their intrinsic value. The GF Valuation label classifies WST as "Modestly Undervalued," presenting an opportunity for long-term investors, although caution is warranted due to the stock's recent price performance and market volatility.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Given the current undervaluation, there may be opportunities for price appreciation; however, potential investors should be mindful of market conditions that could impact the stock's future performance.

How Does WST's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 42.3x 43.5x Forward P/E 36.7x N/A West Pharmaceutical Services' current P/E (TTM) of 42.3x is slightly below its 5-year median P/E of 43.5x, indicating that the stock is trading on the lower end of its historical valuation range. The forward P/E of 36.7x further supports this narrative that the stock is reasonably priced relative to its historical valuation. This P/E analysis aligns with the GF Value™ verdict, reinforcing the view that WST is modestly undervalued.

What Does WST's GF Score™ Tell Us? Metric Rating GF Score™ 96 Financial Strength 9/10 Profitability 9/10 Growth 9/10 Valuation 10/10 Momentum 8/10 The GF Score™ of 96/100 reflects the company's overall strong performance across several key areas. West Pharmaceutical Services excels particularly in Valuation with a perfect score of 10/10, indicating that the stock is favorably priced. Financial Strength, Profitability, and Growth all receive high marks of 9/10, underscoring the company's solid financial foundation and robust growth potential. The Momentum Rank of 8/10 suggests a healthy upward price trajectory, though there may be some fluctuations as indicated by recent insider selling activity.

What Are Insiders Doing with WST Stock? In the past three months, insiders at West Pharmaceutical Services Inc have sold approximately $1.1 million worth of shares, with no reported buying activity. This trend of insider selling could suggest a lack of confidence in the stock price's immediate future or possibly a strategic move to capitalize on the stock's recent gains. While insider selling does not necessarily indicate a negative outlook, it is an important signal for investors to consider when evaluating the stock's potential performance.

What This Means for Investors Based on the GF Value™, West Pharmaceutical Services Inc is currently undervalued, presenting a potential opportunity for long-term gains. However, the recent insider selling and market fluctuations warrant a cautious approach as investors assess their strategies moving forward.

For the complete analysis, visit the West Pharmaceutical Services Inc WST stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is WST's GF Score™?

WST's GF Score™ is 96/100, indicating a strong investment opportunity based on various financial metrics.

Is WST overvalued or undervalued?

WST is currently undervalued with a GF Value™ estimate indicating a 12.1% margin of safety.

What is WST's P/E ratio?

WST's P/E (TTM) is 42.3x, which is slightly below its 5-year median of 43.5x, suggesting that the stock is trading at a favorable valuation compared to its historical norms.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel ​Lagarde as its top boss, effective ‌August 31, succeeding longtime chief Eric Green.

Atmos Energy (ATO - Free Report) came out with quarterly earnings of $3.47 per share, beating the Zacks Consensus Estimate of $3.37 per share. This compares to earnings of $3.03 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +3.07%. A quarter ago, it was expected that this natural gas utility would post earnings of $2.41 per share when it actually produced earnings of $2.44, delivering a surprise of +1.24%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Atmos, which belongs to the Zacks Utility - Gas Distribution industry, posted revenues of $1.96 billion for the quarter ended March 2026, missing the Zacks Consensus Estimate by 12.33%. This compares to year-ago revenues of $1.95 billion. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Atmos shares have added about 11.7% since the beginning of the year versus the S&P 500's gain of 6%.

What's Next for Atmos?While Atmos has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Atmos was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.32 on $1.05 billion in revenues for the coming quarter and $8.30 on $5.56 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Utility - Gas Distribution is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the broader Zacks Utilities sector, Consolidated Water (CWCO - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.

This developer and operator of desalination plants is expected to post quarterly earnings of $0.27 per share in its upcoming report, which represents a year-over-year change of -12.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Consolidated Water's revenues are expected to be $33.4 million, down 1% from the year-ago quarter.

Atmos Energy Corporation (ATO) Q2 2026 Earnings Call Transcript